Liquidata Share/ETF/Trust Analysis
Portfolio Holdings Detail for ISIN IE00BF4RFH31
| Stock Name / Fund | iShares MSCI World Small Cap UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares III Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300PZLRJB7M8H1057 |
| ETF Ticker | WSML(USD) LSE |
| ETF Ticker | WLDS(GBP) LSE |
| ETF Ticker | IUSN(EUR) F |
| ETF Ticker | IUSN.DE(EUR) CXE |
| ETF Ticker | WLDS.LS(GBP) CXE |
| ETF Ticker | WSML.LS(USD) CXE |
| ETF Ticker | WSML.L(GBP) LSE |
| ETF Ticker | WLDS.L(GBP) LSE |
Holdings detail for EXEL
| Stock Name | Exelixis Inc |
| Ticker | EXEL(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US30161Q1040 |
Show aggregate EXEL holdings
News associated with EXEL
- Exelixis (NASDAQ:EXEL) Price Target Raised to $50.00 at Morgan Stanley
- Exelixis (NASDAQ:EXEL – Get Free Report) had its price objective lifted by investment analysts at Morgan Stanley from $46.00 to $50.00 in a report issued on Wednesday, MarketBeat Ratings reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. Morgan Stanley’s price target suggests a potential upside of 23.61% from the company’s […] - 2025-09-19 02:36:46
- Exelixis (NASDAQ:EXEL) Rating Increased to Hold at Barclays
- Barclays upgraded shares of Exelixis (NASDAQ:EXEL – Free Report) to a hold rating in a research report report published on Tuesday morning,Zacks.com reports. A number of other analysts also recently weighed in on the company. Bank of America lifted their price target on Exelixis from $45.00 to $46.00 and gave the company a “neutral” rating […] - 2025-09-19 02:02:49
- Exelixis (NASDAQ:EXEL) Rating Lowered to “Hold” at Wall Street Zen
- Exelixis (NASDAQ:EXEL – Get Free Report) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Monday. Several other equities analysts have also recently issued reports on the company. Guggenheim reiterated a “buy” rating and issued a $45.00 price objective on shares of Exelixis in a […] - 2025-09-15 02:06:56
- Zacks Research Predicts Exelixis’ Q3 Earnings (NASDAQ:EXEL)
- Exelixis, Inc. (NASDAQ:EXEL – Free Report) – Research analysts at Zacks Research dropped their Q3 2026 earnings estimates for shares of Exelixis in a research report issued on Wednesday, August 27th. Zacks Research analyst Team now anticipates that the biotechnology company will earn $0.62 per share for the quarter, down from their previous estimate of […] - 2025-09-01 02:44:58
- Exelixis, Inc. (NASDAQ:EXEL) Receives Average Recommendation of “Moderate Buy” from Analysts
- Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty-two ratings firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and thirteen have assigned a buy recommendation to the […] - 2025-08-18 05:10:57
- Exelixis, Inc. (NASDAQ:EXEL) Shares Acquired by LPL Financial LLC
- LPL Financial LLC lifted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 74.5% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 187,097 shares of the biotechnology company’s stock after purchasing an additional 79,885 shares during the period. LPL Financial LLC’s holdings […] - 2025-08-11 05:34:56
- Exelixis, Inc. (NASDAQ:EXEL) Position Increased by Natixis Advisors LLC
- Natixis Advisors LLC boosted its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 14.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 69,922 shares of the biotechnology company’s stock after purchasing an additional 9,072 shares during the period. […] - 2025-08-08 05:18:54
- Wall Street Zen Downgrades Exelixis (NASDAQ:EXEL) to Buy
- Exelixis (NASDAQ:EXEL – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a note issued to investors on Saturday. Several other equities analysts also recently commented on the stock. HC Wainwright upped their price target on shares of Exelixis from $47.00 to $53.00 […] - 2025-08-04 04:27:00
- Exelixis (NASDAQ:EXEL) Given “Market Outperform” Rating at JMP Securities
- Exelixis (NASDAQ:EXEL – Get Free Report)‘s stock had its “market outperform” rating restated by equities research analysts at JMP Securities in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $50.00 target price on the biotechnology company’s stock. JMP Securities’ price objective would suggest a potential upside of 35.69% […] - 2025-07-31 04:18:47
- Noteworthy ETF Outflows: XBI, MRNA, ALNY, EXEL
- Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $225.3 million dollar outflow -- that's a 4.6% decrease week over week - 2025-07-30 11:49:03
- Truist Financial Has Lowered Expectations for Exelixis (NASDAQ:EXEL) Stock Price
- Exelixis (NASDAQ:EXEL – Free Report) had its price objective trimmed by Truist Financial from $56.00 to $49.00 in a research report released on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock. A number of other research firms have also recently weighed in on EXEL. Benchmark reiterated a “neutral” rating […] - 2025-07-30 06:13:05
- Exelixis (NASDAQ:EXEL) Given “Outperform” Rating at William Blair
- William Blair restated their outperform rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a research note published on Tuesday morning,RTT News reports. Several other analysts also recently commented on EXEL. Wells Fargo & Company reiterated a “market outperform” rating on shares of Exelixis in a research report on Thursday, April 17th. Jefferies Financial […] - 2025-07-30 04:54:52
- Exelixis (NASDAQ:EXEL) Given New $45.00 Price Target at Royal Bank Of Canada
- Exelixis (NASDAQ:EXEL – Free Report) had its target price cut by Royal Bank Of Canada from $50.00 to $45.00 in a research report report published on Tuesday,Benzinga reports. They currently have a sector perform rating on the biotechnology company’s stock. EXEL has been the subject of several other research reports. Truist Financial boosted their target […] - 2025-07-30 04:54:49
- Morgan Stanley Cuts Exelixis (NASDAQ:EXEL) Price Target to $46.00
- Exelixis (NASDAQ:EXEL – Free Report) had its target price decreased by Morgan Stanley from $48.00 to $46.00 in a report released on Tuesday morning,Benzinga reports. Morgan Stanley currently has an overweight rating on the biotechnology company’s stock. EXEL has been the subject of several other reports. Stephens upgraded Exelixis from an “equal weight” rating to […] - 2025-07-30 04:20:59
- Exelixis Target of Unusually Large Options Trading (NASDAQ:EXEL)
- Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) was the target of some unusual options trading activity on Tuesday. Stock traders acquired 12,250 call options on the stock. This is an increase of 373% compared to the typical volume of 2,588 call options. Wall Street Analysts Forecast Growth Several brokerages have issued reports on EXEL. Morgan […] - 2025-07-30 03:07:01
- Exelixis (NASDAQ:EXEL) Shares Gap Down on Analyst Downgrade
- Exelixis, Inc. (NASDAQ:EXEL – Get Free Report)’s share price gapped down before the market opened on Tuesday after Truist Financial lowered their price target on the stock from $56.00 to $49.00. The stock had previously closed at $44.39, but opened at $38.26. Truist Financial currently has a buy rating on the stock. Exelixis shares last […] - 2025-07-30 03:06:57
- Arizona State Retirement System Sells 790 Shares of Exelixis, Inc. (NASDAQ:EXEL)
- Arizona State Retirement System trimmed its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 1.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 73,696 shares of the biotechnology company’s stock after selling 790 shares during the period. Arizona […] - 2025-07-17 06:56:52
- Exelixis, Inc. (NASDAQ:EXEL) Shares Purchased by Cerity Partners LLC
- Cerity Partners LLC boosted its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 127.3% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 167,915 shares of the biotechnology company’s stock after purchasing an additional 94,031 shares during the quarter. Cerity Partners LLC owned […] - 2025-07-16 06:51:24
- Exelixis, Inc. (NASDAQ:EXEL) Holdings Reduced by Alps Advisors Inc.
- Alps Advisors Inc. decreased its position in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 25.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 9,709 shares of the biotechnology company’s stock after selling 3,291 shares during the period. Alps Advisors Inc.’s holdings […] - 2025-07-16 05:23:13
- Bank of New York Mellon Corp Grows Position in Exelixis, Inc. (NASDAQ:EXEL)
- Bank of New York Mellon Corp lifted its stake in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 0.6% in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,476,857 shares of the biotechnology company’s stock after purchasing an additional 15,239 shares during the quarter. Bank […] - 2025-07-11 06:13:00
- Principal Financial Group Inc. Sells 14,218 Shares of Exelixis, Inc. (NASDAQ:EXEL)
- Principal Financial Group Inc. lessened its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 2.1% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 648,218 shares of the biotechnology company’s stock after selling 14,218 shares during the period. Principal Financial Group Inc. owned approximately 0.24% […] - 2025-07-09 05:51:35
- Traders Buy Large Volume of Call Options on Exelixis (NASDAQ:EXEL)
- Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) was the recipient of unusually large options trading activity on Monday. Traders purchased 3,495 call options on the stock. This is an increase of 56% compared to the typical daily volume of 2,238 call options. Insider Activity In other Exelixis news, Director Sue Gail Eckhardt sold 18,838 shares […] - 2025-07-09 02:50:45
- Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by New York State Teachers Retirement System
- New York State Teachers Retirement System cut its stake in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 12.8% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 359,105 shares of the biotechnology company’s stock after selling 52,707 shares during the period. New York State Teachers Retirement […] - 2025-07-04 05:31:06
- HC Wainwright Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) Stock
- Exelixis (NASDAQ:EXEL – Get Free Report) had its price objective hoisted by research analysts at HC Wainwright from $47.00 to $53.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 21.50% from […] - 2025-07-02 03:02:56
- Bartlett & CO. Wealth Management LLC Makes New $37,000 Investment in Exelixis, Inc. (NASDAQ:EXEL)
- Bartlett & CO. Wealth Management LLC purchased a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 1,000 shares of the biotechnology company’s stock, valued at approximately $37,000. A number of other hedge […] - 2025-06-30 06:44:51
- Exelixis (NASDAQ:EXEL) Raised to “Overweight” at Stephens
- Exelixis (NASDAQ:EXEL – Get Free Report) was upgraded by research analysts at Stephens from an “equal weight” rating to an “overweight” rating in a research note issued on Tuesday, Marketbeat Ratings reports. The firm presently has a $60.00 target price on the biotechnology company’s stock, up from their prior target price of $29.00. Stephens’ price […] - 2025-06-26 02:48:49
- Exelixis (NASDAQ:EXEL) Shares Gap Up on Analyst Upgrade
- Exelixis, Inc. (NASDAQ:EXEL – Get Free Report)’s stock price gapped up prior to trading on Monday after Stephens upgraded the stock from an equal weight rating to an overweight rating. The stock had previously closed at $40.37, but opened at $49.43. Stephens now has a $60.00 price target on the stock, up from their previous […] - 2025-06-25 02:18:52
- Exelixis (NASDAQ:EXEL) Reaches New 52-Week High After Analyst Upgrade
- Shares of Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) reached a new 52-week high during trading on Tuesday after Stephens upgraded the stock from an equal weight rating to an overweight rating. Stephens now has a $60.00 price target on the stock, up from their previous price target of $29.00. Exelixis traded as high as […] - 2025-06-25 02:18:49
- Blue Trust Inc. Increases Holdings in Exelixis, Inc. (NASDAQ:EXEL)
- Blue Trust Inc. increased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 15.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 12,976 shares of the biotechnology company’s stock after purchasing an additional 1,745 shares during the period. […] - 2025-06-22 05:22:52
- Exelixis, Inc. (NASDAQ:EXEL) Shares Bought by Farther Finance Advisors LLC
- Farther Finance Advisors LLC increased its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 6.1% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,372 shares of the biotechnology company’s stock after acquiring an additional 307 shares during the quarter. Farther Finance Advisors […] - 2025-06-20 04:26:51
iShares MSCI World Small Cap UCITS ETF USD (Acc) EXEL holdings
| Date | Number of EXEL Shares Held | Base Market Value of EXEL Shares | Local Market Value of EXEL Shares | Change in EXEL Shares Held | Change in EXEL Base Value | Current Price per EXEL Share Held | Previous Price per EXEL Share Held |
|---|
| 2025-10-15 (Wednesday) | 186,056 | USD 7,447,822 | USD 7,447,822 | | | | |
| 2025-10-10 (Friday) | 184,943 | USD 7,055,575 | USD 7,055,575 | | | | |
| 2025-10-08 (Wednesday) | 184,943 | USD 7,146,198 | USD 7,146,198 | | | | |
| 2025-10-07 (Tuesday) | 184,943 | USD 7,329,291 | USD 7,329,291 | 742 | USD -40,591 | USD 39.63 | USD 40.01 |
| 2025-10-06 (Monday) | 184,201 | USD 7,369,882 | USD 7,369,882 | 0 | USD -14,736 | USD 40.01 | USD 40.09 |
| 2025-10-03 (Friday) | 184,201 | USD 7,384,618 | USD 7,384,618 | 0 | USD -232,093 | USD 40.09 | USD 41.35 |
| 2025-10-02 (Thursday) | 184,201 | USD 7,616,711 | USD 7,616,711 | 0 | USD 27,630 | USD 41.35 | USD 41.2 |
| 2025-10-01 (Wednesday) | 184,201 | USD 7,589,081 | USD 7,589,081 | 0 | USD -18,420 | USD 41.2 | USD 41.3 |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of EXEL by Blackrock for IE00BF4RFH31
Show aggregate share trades of EXEL| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-10-07 | BUY | 742 | | | 39.630* | | 37.87 |
| 2025-09-30 | BUY | 8,335 | | | 41.300* | | 37.79 |
| 2025-09-08 | SELL | -1,416 | | | 37.690* | | 37.75 Profit of 53,454 on sale |
| 2025-08-15 | BUY | 708 | | | 38.310* | | 37.75 |
| 2025-08-07 | BUY | 2,124 | | | 37.390* | | 37.74 |
| 2025-07-29 | BUY | 708 | | | 36.940* | | 37.77 |
| 2025-07-14 | BUY | 1,360 | | | 45.580* | | 37.45 |
| 2025-06-30 | BUY | 1,360 | | | 44.075* | | 37.10 |
| 2025-06-25 | BUY | 2,040 | | | 43.530* | | 36.97 |
| 2025-06-20 | SELL | -340 | | | 40.370* | | 36.83 Profit of 12,524 on sale |
| 2025-06-12 | SELL | -2,728 | | | 41.780* | | 36.63 Profit of 99,931 on sale |
| 2025-06-02 | BUY | 1,020 | | | 42.880* | | 36.26 |
| 2025-05-30 | SELL | -12,503 | | | 43.040* | | 36.20 Profit of 452,619 on sale |
| 2025-05-28 | BUY | 734 | | | 42.410* | | 36.10 |
| 2025-05-15 | BUY | 367 | | | 46.260* | | 35.48 |
| 2025-05-13 | BUY | 734 | | | 36.950* | | 35.38 |
| 2025-05-07 | BUY | 1,101 | | | 36.810* | | 35.33 |
| 2025-04-28 | BUY | 367 | | | 38.440* | | 35.09 |
| 2025-04-16 | BUY | 4,771 | | | 36.150* | | 34.97 |
| 2025-04-14 | BUY | 734 | | | 35.740* | | 34.94 |
| 2025-04-08 | SELL | -734 | | | 34.130* | | 34.95 Profit of 25,654 on sale |
| 2025-04-04 | SELL | -738 | | | 34.570* | | 34.96 Profit of 25,798 on sale |
| 2025-03-28 | BUY | 3,670 | | | 36.700* | | 34.87 |
| 2025-03-12 | SELL | -734 | | | 37.200* | | 34.48 Profit of 25,310 on sale |
| 2025-03-04 | SELL | -734 | | | 38.290* | | 34.18 Profit of 25,087 on sale |
| 2025-02-26 | SELL | -1,468 | | | 37.530* | | 33.91 Profit of 49,783 on sale |
| 2025-02-13 | BUY | 8,222 | | | 34.490* | | 33.62 |
| 2025-02-12 | BUY | 1,404 | | | 32.800* | | 33.64 |
| 2025-01-27 | BUY | 351 | | | 32.730* | | 33.81 |
| 2025-01-23 | BUY | 351 | | | 34.130* | | 33.84 |
| 2024-12-09 | BUY | 12,636 | | | 35.170* | | 33.78 |
| 2024-12-04 | BUY | 702 | | | 35.770* | | 33.57 |
| 2024-12-03 | BUY | 1,053 | | | 35.260* | | 33.51 |
| 2024-11-19 | BUY | 2,106 | | | 34.410* | | 32.33 |
| 2024-11-18 | BUY | 702 | | | 34.520* | | 32.20 |
| 2024-11-12 | BUY | 1,404 | | | 35.850* | | 31.97 |
| 2024-11-11 | BUY | 351 | | | 36.190* | | 31.69 |
| 2024-11-07 | BUY | 1,745 | | | 35.800* | | 31.03 |
| 2024-10-23 | BUY | 702 | | | 28.320* | | 28.74 |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of EXEL
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 349,384 | 0 | 595,253 | 58.7% |
| 2025-09-18 | 430,450 | 11,761 | 708,167 | 60.8% |
| 2025-09-17 | 504,083 | 1,036 | 836,321 | 60.3% |
| 2025-09-16 | 404,430 | 0 | 563,875 | 71.7% |
| 2025-09-15 | 329,606 | 441 | 529,065 | 62.3% |
| 2025-09-12 | 524,842 | 4,207 | 913,692 | 57.4% |
| 2025-09-11 | 562,177 | 3,134 | 902,871 | 62.3% |
| 2025-09-10 | 572,567 | 3,800 | 905,184 | 63.3% |
| 2025-09-09 | 397,859 | 8,844 | 684,471 | 58.1% |
| 2025-09-08 | 313,702 | 25 | 519,022 | 60.4% |
| 2025-09-05 | 559,014 | 1,313 | 808,217 | 69.2% |
| 2025-09-04 | 422,907 | 6,992 | 675,247 | 62.6% |
| 2025-09-03 | 599,362 | 2,245 | 1,023,151 | 58.6% |
| 2025-09-02 | 1,012,249 | 954 | 1,595,650 | 63.4% |
| 2025-08-29 | 501,443 | 2,883 | 758,573 | 66.1% |
| 2025-08-28 | 476,124 | 1,667 | 704,826 | 67.6% |
| 2025-08-27 | 441,436 | 666 | 588,517 | 75.0% |
| 2025-08-26 | 399,893 | 1,239 | 562,757 | 71.1% |
| 2025-08-25 | 355,644 | 31 | 551,409 | 64.5% |
| 2025-08-22 | 308,605 | 540 | 468,551 | 65.9% |
| 2025-08-21 | 589,902 | 0 | 745,828 | 79.1% |
| 2025-08-20 | 385,633 | 314 | 503,585 | 76.6% |
| 2025-08-19 | 433,048 | 813 | 690,899 | 62.7% |
| 2025-08-18 | 468,009 | 321 | 691,081 | 67.7% |
| 2025-08-15 | 387,499 | 29,516 | 649,336 | 59.7% |
| 2025-08-14 | 510,428 | 160 | 775,522 | 65.8% |
| 2025-08-13 | 508,860 | 520 | 720,588 | 70.6% |
| 2025-08-12 | 564,759 | 583 | 792,782 | 71.2% |
| 2025-08-11 | 531,570 | 150 | 830,838 | 64.0% |
| 2025-08-08 | 501,446 | 198 | 911,580 | 55.0% |
| 2025-08-07 | 716,346 | 129 | 1,140,877 | 62.8% |
| 2025-08-06 | 568,916 | 378 | 881,700 | 64.5% |
| 2025-08-05 | 682,745 | 15,446 | 1,418,128 | 48.1% |
| 2025-08-04 | 976,230 | 24 | 1,600,059 | 61.0% |
| 2025-08-01 | 1,884,490 | 117 | 2,637,563 | 71.4% |
| 2025-07-31 | 1,209,024 | 2,215 | 1,711,147 | 70.7% |
| 2025-07-30 | 912,071 | 37,267 | 1,899,827 | 48.0% |
| 2025-07-29 | 4,273,219 | 106,296 | 7,518,518 | 56.8% |
| 2025-07-28 | 1,728,119 | 875 | 2,115,607 | 81.7% |
| 2025-07-25 | 843,185 | 401 | 1,143,922 | 73.7% |
| 2025-07-24 | 436,484 | 322 | 684,873 | 63.7% |
| 2025-07-23 | 587,574 | 1,065 | 808,716 | 72.7% |
| 2025-07-22 | 495,903 | 110 | 758,132 | 65.4% |
| 2025-07-21 | 417,849 | 0 | 569,349 | 73.4% |
| 2025-07-18 | 376,445 | 1 | 509,088 | 73.9% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Disclaimer
All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.